-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, the Wuhan Municipal Medical Insurance Bureau issued a notice to dynamically adjust the information of some drugs listed on the Internet, involving newly marketed drugs, patented drugs, drugs that are prone to shortage, over-rated generic drugs, common generic drugs, e.
12 companies have 18 generic names and 25 listed dru.
The price of online medicines has been lowered, from 01 yuan to 563 yu.
In addition, the prices and medical insurance payment standards for centralized procurement of drugs with one generic name and two drugs from one company were adjust.
It is understood that on May 14, Wuhan City has adjusted the online prices of 32 drugs under 31 generic names of 23 companies and the specifications of 2 drugs, and the online prices of 32 drugs have been reduced by 01-650 Yuan vari.
Among them, the one with the highest price reduction is undoubtedly lenvatinib mesylate capsules, a first-line targeted drug for liver cancer treatme.
The drug was launched in China in September 2018 at a price of 16,800 yuan/box (4mg x 30 capsules/bo.
In December 2020, through medical insurance negotiation, lenvatinib mesylate capsules were reduced by 80% and entered the National Medical Insurance Drug Li.
The adjustment this time is the lenvatinib mesylate capsules produced by Qilu Pharmaceutic.
The drug was officially launched on October 22 last year at 2,750 yuan/box (the specification is 4mg×30 capsules/bo.
2750 yuan/box has been reduced to 2100 yuan/b.
The industry believes that because the price of drugs listed on the Internet is the highest retail price or ceiling price of public medical institutions in the ci.
For the citizens of Wuhan, this means that a large number of medicines will be reduced in price in the city's public medical institutio.
In addition to Wuhan City, on the 25th, the Sichuan Provincial Pharmaceutical Equipment Bidding and Procurement Service Center also announced a notice on the price reduction of some dru.
After sorting out, it is found that a total of 712 batches of drugs have adjusted their prices this time, of which 5 batches of drugs applied for adjustment due to errors in the smallest preparation unit, and 28 batches of drugs have new linkage reference pric.
Specifically, the Ganmaojiedu granules (5g) in the minimum preparation unit error were adjusted from the original 258 yuan to 25 yuan; the levofloxacin tablet (25g) was adjusted from the original 400 yuan to 40 yuan; the levofloxacin tablet (5g) was adjusted from the original Yuanhu Zhitong Granules (5g) changed from 296 yuan to 39 yu.
Industry analysts believe that there are continuous drug price reductions, mainly due to the normalization and intensification of the centralized procurement of drugs from the state to the local ar.
Medical prices are inflat.
In this regard, the industry believes that, in the "14th Five-Year Plan" period, the National Medical Insurance Bureau has made it clear that the centralized procurement of drugs and medical consumables will be increased, and the centralized procurement of medical supplies will be promoted to become the dominant model, and the national centralized drug procurement will be carried out in a normalized and institutionalized mann.
Under the background of continuous expansion of the scope of high-value medical consumables centralized and bulk procurement, there will be a large number of medicines and consumables in the future, and they will not escape the fate of price reducti.
For pharmaceutical companies, in the future, it is necessary to accelerate the research and development of innovative products, have more products with core competitiveness, do a good job of consistency evaluation, and actively participate in the centralized procurement of drugs by the country and provinces, so as to remain competitive in the mark.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
12 companies have 18 generic names and 25 listed dru.
The price of online medicines has been lowered, from 01 yuan to 563 yu.
In addition, the prices and medical insurance payment standards for centralized procurement of drugs with one generic name and two drugs from one company were adjust.
It is understood that on May 14, Wuhan City has adjusted the online prices of 32 drugs under 31 generic names of 23 companies and the specifications of 2 drugs, and the online prices of 32 drugs have been reduced by 01-650 Yuan vari.
Among them, the one with the highest price reduction is undoubtedly lenvatinib mesylate capsules, a first-line targeted drug for liver cancer treatme.
The drug was launched in China in September 2018 at a price of 16,800 yuan/box (4mg x 30 capsules/bo.
In December 2020, through medical insurance negotiation, lenvatinib mesylate capsules were reduced by 80% and entered the National Medical Insurance Drug Li.
The adjustment this time is the lenvatinib mesylate capsules produced by Qilu Pharmaceutic.
The drug was officially launched on October 22 last year at 2,750 yuan/box (the specification is 4mg×30 capsules/bo.
2750 yuan/box has been reduced to 2100 yuan/b.
The industry believes that because the price of drugs listed on the Internet is the highest retail price or ceiling price of public medical institutions in the ci.
For the citizens of Wuhan, this means that a large number of medicines will be reduced in price in the city's public medical institutio.
In addition to Wuhan City, on the 25th, the Sichuan Provincial Pharmaceutical Equipment Bidding and Procurement Service Center also announced a notice on the price reduction of some dru.
After sorting out, it is found that a total of 712 batches of drugs have adjusted their prices this time, of which 5 batches of drugs applied for adjustment due to errors in the smallest preparation unit, and 28 batches of drugs have new linkage reference pric.
Specifically, the Ganmaojiedu granules (5g) in the minimum preparation unit error were adjusted from the original 258 yuan to 25 yuan; the levofloxacin tablet (25g) was adjusted from the original 400 yuan to 40 yuan; the levofloxacin tablet (5g) was adjusted from the original Yuanhu Zhitong Granules (5g) changed from 296 yuan to 39 yu.
Industry analysts believe that there are continuous drug price reductions, mainly due to the normalization and intensification of the centralized procurement of drugs from the state to the local ar.
Medical prices are inflat.
In this regard, the industry believes that, in the "14th Five-Year Plan" period, the National Medical Insurance Bureau has made it clear that the centralized procurement of drugs and medical consumables will be increased, and the centralized procurement of medical supplies will be promoted to become the dominant model, and the national centralized drug procurement will be carried out in a normalized and institutionalized mann.
Under the background of continuous expansion of the scope of high-value medical consumables centralized and bulk procurement, there will be a large number of medicines and consumables in the future, and they will not escape the fate of price reducti.
For pharmaceutical companies, in the future, it is necessary to accelerate the research and development of innovative products, have more products with core competitiveness, do a good job of consistency evaluation, and actively participate in the centralized procurement of drugs by the country and provinces, so as to remain competitive in the mark.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Click to enter the exhibition page
